Drug Search Results
More Filters [+]

Tesevatinib

Alternative Names: tesevatinib, xl647, kd019
Latest Update: 2023-02-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: EGFR Inhibitor,ERBB2 Inhibitor,VEGFR Inhibitor,TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tesevatinib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Arthrogryposis|Kidney Diseases, Cystic|Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACT17675

P2

Completed

Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant|Arthrogryposis|Kidney Diseases, Cystic

2022-01-25

Recent News Events